Evidence map›Paper›PMID 42233020›Full record

ArticleFrontiers in immunology2026

The B7-H3/CD3 immune phenotype identifies prognostic subgroups in neuroblastoma.

Petar Rasic, Gordana Samardzija, Slavisa M Djuricic, Nemanja Mitrovic, Ana Bogosavljevic, Andjela Milicevic, Ivan Soldatovic, Olivera Stefanovic, Nada Krstovski, Milos Kuzmanovic and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Petar RasicDepartment of Abdominal Surgery, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Gordana SamardzijaDepartment of Clinical Pathology, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Slavisa M DjuricicFaculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Nemanja MitrovicDepartment of Clinical Pathology, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Ana BogosavljevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Andjela MilicevicDepartment of Pathology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Ivan SoldatovicInstitute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Olivera StefanovicDepartment of Abdominal Surgery, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Nada KrstovskiFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Milos KuzmanovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Dragana AleksicDepartment of Hematology and Oncology, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Danka RedzicDepartment of Hematology and Oncology, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Predrag RodicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena LazicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Goran MilosevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jovana SvorcanDepartment of Hematology and Oncology, University Children's Hospital, Belgrade, Serbia.
Ratko RadetaDepartment of Hematology and Oncology, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Maja Milickovic *Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Belgrade, Serbia.
Dusko Dundjerovic *Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: B7-H3 is an immune checkpoint molecule implicated in tumor immune evasion and adverse prognosis in multiple malignancies. This study aimed to characterize the relationships between tumor-cell B7-H3 expression, immune-cell infiltration, clinicopathological features, and survival in malignant neuroblastic tumors, and to define an immune phenotype with potential translational relevance. Methods: We retrospectively analyzed a population-representative cohort of 81 patients with neuroblastoma or nodular ganglioneuroblastoma diagnosed between 2009 and 2020. B7-H3 expression and CD3 Results: Tumors with high B7-H3 expression demonstrated reduced CD8 Conclusion: The B7-H3 low/CD3 high immune phenotype identifies patients with markedly favorable survival in malignant neuroblastic tumors and retains a protective association after adjustment for established clinical prognostic factors. However, given the limited statistical power of the current cohort, the overall incremental prognostic value of combined B7-H3/CD3 phenotyping requires evaluation in larger, independent cohorts.

Indexed as

B7 AntigensCD3 ComplexNeuroblastomaBiomarkers, TumorChildChild, PreschoolFemaleHumansInfantLymphocytes, Tumor-InfiltratingMalePhenotypePrognosisRetrospective StudiesB7 AntigensBiomarkers, TumorCD276 protein, humanCD3 ComplexB7-H3CD3CD8immune cell infiltrationimmune phenotypeneuroblastomaprognosissurvival

Identifiers

PMID42233020
PMCPMC13223607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.